Solasia Pharma KK (JP:4597) has released an update.
Solasia Pharma K.K. has released its consolidated financial results for the second quarter of FY 2024, highlighting its strategic partnerships and progress in the commercialization of its pipeline products, Sancuso® and DARVIAS®. In China, after transferring sales functions to Lee’s Pharmaceutical, approval for a manufacturing facility change could reduce production costs, despite a temporary sales volume dip. DARVIAS® has received marketing approval in Japan and is preparing for regulatory approval in South America, with ongoing negotiations for out-licensing in China and a Named Patient Program facilitating access in other regions.
For further insights into JP:4597 stock, check out TipRanks’ Stock Analysis page.
